Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Tumor necrosis factor-alpha (TNFα) drives pathologic platelet hyperreactivity through signaling on hematopoietic stem/progenitor cells and expansion of canonical megakaryocytic progenitors.

Joshua Siner, Molly Brakhane, Katrina Ashworth, Christopher Letson, Lili Antunes Heck, Nina Lasky, Thomas Girard, Stephen Oh, Jorge Di Paola

Blood (2025) 146 (Supplement 1): 1250.

https://doi.org/10.1182/blood-2025-1250

Published: 2025

Journal Articles

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Stephen Oh, Juan Carlos Hernandez Boluda, Jean-Jacques Kiladjian, Viviane Dubruille, Christian Recher, Alexandre Lockhart, Chandan Kumar, Hanny Musa, Jasmine Sahni, Dwaipayan Patnaik, Claire Harrison

Blood (2025) 146 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2025-2025

Published: 2025

Journal Articles

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Francesca Palandri, Nicolaas Schaap, Jérôme Rey, Nikolas Von Bubnoff, Andreas Reiter, Juan Carlos Hernandez Boluda, Timothy Devos, Bethan Psaila, Donal McLornan, Catherine Ellis, Fulya Sen Nikitas, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Stephen Oh

Blood (2025) 146 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2025-2023

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Journal Articles

A novel in-frame calreticulin mutation induces activation of JAK-STAT signaling and thrombocytosis

Abigail Runnels, Nicole Arellano, Ling Huang, Saveg Yadav, Maihi Skeen, William Heaton, Cameron Hoppensteadt, Molly Brakhane, Stephen Oh, Shannon Elf

Blood (2025) 146 (Supplement 1): 358.

https://doi.org/10.1182/blood-2025-358

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Interleukin-12 and TNFα signaling drives parallel evolution of independent leukemic clones in JAK2V617F mutant myeloproliferative neoplasms

Tyler Parsons, Aishwarya Krishnan, Infencia Xavier Raj, Maggie Cox, Stephen Oh, Grant Challen

Blood (2025) 146 (Supplement 1): 5538.

https://doi.org/10.1182/blood-2025-5538

Published: 2025

Journal Articles

Activating STIM1 mutations drive the development of myelofibrosis

Molly Brakhane, Vittorio Abbonante, Angelo Laranjeira, Christian Di Buduo, Brooke Sadler, Katrina Ashworth, Tim Kong, Christopher Letson, Fan He, Mary Fulbright, Joshua Siner, Dong Chen, Regina Clemens, Elena Pegoraro, Michele Lambert, Kandace Gollomp, Jorge Di Paola, Alessandra Balduini, Stephen Oh

Blood (2025) 146 (Supplement 1): 5528.

https://doi.org/10.1182/blood-2025-5528

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL

Stephen Oh, Michael Grunwald, TaeHyung (Simon) Kim, Erin Crowgey, J.E. Hamer-Maansson, Ahmad Naim, Valkal Bhatt, Jeffrey Zwicker

Blood (2025) 146 (Supplement 1): 3749.

https://doi.org/10.1182/blood-2025-3749

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2024-194551

Published: 2024

Journal Articles

Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1

Fan He, Shuyang Lin, Tim Kong, Daniel Fisher, Alexander Kim, Molly Brakhane, Christopher Letson, Yanbo Yu, Noelle Champagne, Mary Fulbright, Varun Ramesh, Angelo Laranjeira, Maggie Cox, Katrina Ashworth, Stephen Sykes, Jorge Di Paola, Stephen Oh

Blood (2024) 144 (Supplement 1): 875.

https://doi.org/10.1182/blood-2024-211520

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

Construction of a Myeloid Gene Signature Revealing Novel Therapeutic Targets for Myeloid Malignancies

Fan He, Shuyang Lin, Bei Gao, Varun Ramesh, Alexander Kim, Tim Kong, Noelle Champagne, Mary Fulbright, Daniel Fisher, Christopher Letson, Molly Brakhane, Yanbo Yu, Marco Sardiello, Stephen Sykes, Jorge Di Paola, Stephen Oh

Blood (2024) 144 (Supplement 1): 6161.

https://doi.org/10.1182/blood-2024-212168

Published: 2024

Journal Articles

JAK2-V617F Expression Results in a Cell-Intrinsic Expansion of Megakaryocyte Progenitors with Evidence of Myc Pathway Activation in Both Mature and Precursor Megakaryocytes By Single Cell RNA Sequencing

Joshua Siner, Jun Xia, Juo-Chin Yao, Kartik Singhal, Daniel Fisher, Lilian Antunes Heck, Malachi Griffith, Stephen Oh, Jorge Di Paola, Daniel C. Link

Blood (2024) 144 (Supplement 1): 6567.

https://doi.org/10.1182/blood-2024-211373

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

JAK2 V617F Mutant MPN Cells Support Parallel Evolution of Independent Leukemic Clones

Tyler M Parsons, Aishwarya Krishnan, Andrew L Young, Maggie Cox, Stephen Oh, Grant A Challen

Blood (2024) 144 (Supplement 1): 755.

https://doi.org/10.1182/blood-2024-203680

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Tumor necrosis factor-alpha (TNFα) drives pathologic platelet hyperreactivity through signaling on hematopoietic stem/progenitor cells and expansion of canonical megakaryocytic progenitors.

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

A novel in-frame calreticulin mutation induces activation of JAK-STAT signaling and thrombocytosis

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Interleukin-12 and TNFα signaling drives parallel evolution of independent leukemic clones in JAK2V617F mutant myeloproliferative neoplasms

Activating STIM1 mutations drive the development of myelofibrosis

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis

Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1

Construction of a Myeloid Gene Signature Revealing Novel Therapeutic Targets for Myeloid Malignancies

JAK2-V617F Expression Results in a Cell-Intrinsic Expansion of Megakaryocyte Progenitors with Evidence of Myc Pathway Activation in Both Mature and Precursor Megakaryocytes By Single Cell RNA Sequencing

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

JAK2 V617F Mutant MPN Cells Support Parallel Evolution of Independent Leukemic Clones

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only